Help us make childhood cancer universally survivable.

By giving monthly, you directly support our continued research into discovering effective and less toxic treatments for childhood cancer.

Support Our Lab

$
Select Payment Method
Personal Info

Credit Card Info
This is a secure SSL encrypted payment.
Billing Details

I want to dedicate this donation to someone

In honor of... Details

Donation Total: $25.00 One Time

Our team is on a mission to make childhood cancer universally survivable!

Every year, the FDA approves on average 12 drugs to treat adult cancer, but has only approved 8 drugs to treat childhood cancer since 1978. 

Since our inception in 2015, cc-TDI has pushed two drugs into three clinical trials to treat childhood cancer.

Learn More About Our Research

giving back childhood for

#GIVINGBACKCHILDHOOD

Latest News

Postdoctoral Fellowship or Senior Scientist Position

Charles Keller November 25, 2021

Postdoctoral Fellowship or Senior Scientist Position Portland, Oregon USA Are you a PhD developmental biologist, biochemist, molecular biologist, biomedical engineer or stem cell biologist interested to change paradigms and outcomes for cancers of children, adolescents and young adults? cc-TDI offers a mentored research experience for recent PhD graduates or senior scientists in a diverse, inclusive, team-based multidisciplinary setting of biologist and engineers, nestled in a facility with $9M in equipment and automation, rich in conditional mouse models, just minutes from the Portland-area medical center and Intel headquarters in the Silicon Forest.  Your NIH R01-funded research

Read More »
View All Blog Posts

In the Press

Beaverton lab identifies drug that turns off key gene in deadly childhood muscle cancer

By Elizabeth Hayes - Portland Business Journal
The Children's Cancer Therapy Development Institute is studying how a breast cancer drug candidate could impact children with an aggressive tumor in the soft muscle.
Read Article >

Scientists And Parents Band Together To Research Cures For Rare Childhood Cancer

By Esther Landhuis - NPR
Small patient numbers mean there's less motivation to allocate resources to study the diseases and develop potential drugs. Dozens of childhood cancers fall in this category, some so rare that few pediatric oncologists hear about them.
Read Article >

Scientists Tackle Lethal Childhood Brain Cancer

By Esther Landhuis - Scientific American
In precision medicine era, legacy gifts of patient brain tissue reveal disease mechanisms and new therapeutic approaches.
Read Article >

Beaverton's Children's Cancer Therapy Development Institute tackles deadliest child cancers

By Eric Apalategui - Beaverton Valley Times
Beyond an unmarked door into what looks like a shabby old warehouse in Old Town Beaverton, white-coated scientists are working to find ways to treat cancers that kill almost every child they afflict.
Read Article >

Current Research Projects

Patient-specific CSF testing system for medulloblastoma metastasis
We propose a pilot study to (1) design a computational model of patient-specific flow conditions in the vicinity of a brain tumor leptomeningeal metastasis, and (2) to experimentally test whether drug exposures under those flow conditions would be effective against medulloblastoma tumor cells that represent the biology of the patient’s tumor.
Learn More »
Marizomib in Medulloblastoma
The goal of this preclinical study is to validate marizomib as a treatment for medulloblastoma.
Learn More »
CureFast: Creating a Legacy by Accelerating Childhood Cancer Research
One in 5 children with cancer will not survive. We propose to address gaps in basic and translational research by improving model systems for pediatric diseases. To this end, we have developed a Legacy Gift (research autopsy) program called the Cancer Registry for Familial and Sporadic Tumors (CUREfast)
Learn More »
Clear Cell Sarcoma BigData – Drug Discovery
Clear Cell Sarcoma (CCS) is a very rare soft tissue of children and adults. The underlying clinical problem is that only surgery is curative: chemotherapy and radiation are ineffective. Relapse with metastases results in a significant unmet clinical need because surgery is not possible and effective targeted therapies have not yet been developed.
Learn More »
Previous
Next

A dedicated research team

Our research team is exploring and testing state-of-the-art treatment options for the most urgent issues facing children with cancer. 

Working in our own freestanding research institution allows us to act swiftly and nimbly to achieve results—bringing cost control, speed, purpose, and focus to translate effective treatments into the clinic. To get there, we perform basic science and translational research in our industrial modern lab site (a paint factory remodeled by Nike as an off-site creative space), adjacent to the Silicon Forest in Oregon.

Meet the Team